Intragastric injection of botulinum toxin in the treatment of obesity: a single-center study

In recent years, various novel surgical and non-surgical therapeutic options have been developed for treating obesity. Due to its disputed success, intragastric botulinum toxin A (BTX-A) injection is still being debated. We aim to contribute to this controversial issue in the literature by sharing our center's findings regarding intragastric BTX-A injections in the treatment of obesity. Patients with a body mass index (BMI) of greater than 25 kg/m and at least one obesity-related complication, or a BMI of greater than 30 kg/m without complications, were eligible for the study if they were between the ages of 18 and 65. Following the same procedure, two endoscopists administered BTX-A to all patients. All patients were evaluated for obesity by measuring their lipid profile, hormone profile, and insulin resistance level before treatment. In our study on 82 patients, we saw a significant mean weight loss (-9.2 kg,